secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001193125-25-039316
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx FY2024 net loss $107.3M; anito-cel Phase 2 shows 97% ORR, 62% CR/sCR
----------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $625.7M; runway into 2027.
- Collaboration revenue $107.9M in FY2024 vs $110.3M in FY2023.
- Net loss $107.3M for FY2024 vs $70.7M prior year; R&D spend $157.1M.
- Anito-cel pivotal iMMagine-1 data: 97% ORR, 62% CR/sCR (n=86), no delayed neurotoxicities.
- Commercial launch of anito-cel in RRMM planned for 2026; iMMagine-1 update mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312525039316/0001193125-25-039316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312525039316/d904514d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-039316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer